NASDAQ:AIMT
Delisted
Aimmune Therapeutics Stock News
$34.49
+0 (+0%)
At Close: May 27, 2022
Aimmune sees coronavirus slowing down marketing of peanut allergy therapy
07:38pm, Monday, 16'th Mar 2020
Aimmune Therapeutics Inc on Monday warned of a slow launch of its peanut allergy therapy, as its marketing plans take a hit from U.S. authorities’ recommendation of social distancing to conta…
UPDATE 2-Aimmune sees coronavirus slowing down marketing of peanut allergy therapy
07:35pm, Monday, 16'th Mar 2020
Aimmune Therapeutics Inc on Monday warned of a slow launch of its peanut allergy...
Aimmune sees slowdown in launch of peanut allergy therapy due to coronavirus
05:24pm, Monday, 16'th Mar 2020
Aimmune Therapeutics Inc said on Monday the launch of its peanut allergy therapy may be slowed by the spread of coronavirus in the United States.The company said its representatives may not be able…
UPDATE 1-Aimmune sees slowdown in launch of peanut allergy therapy due to coronavirus
05:21pm, Monday, 16'th Mar 2020
(Adds details on therapy, Amarin's launch)
Aimmune sees slowdown in launch of peanut allergy therapy due to coronavirus
05:12pm, Monday, 16'th Mar 2020
The company said its representatives may not be able to provide support to certain clinics administering the therapy as physicians and patients take precautions to avoid exposure to the virus. The vi
Aimmune says peanut allergy therapy launch may be slowed down by coronavirus
04:38pm, Monday, 16'th Mar 2020
Aimmune Therapeutics Inc on Monday said the launch of its peanut allergy therapy may be slowed down by the spread of the coronavirus in the United States.The company’s manufacturing operation…
Aimmune says peanut allergy therapy launch may be slowed down by coronavirus
04:35pm, Monday, 16'th Mar 2020
Aimmune Therapeutics Inc on Monday said the launch of its peanut allergy therapy...
7 Biotech Stocks to Buy and Hold in 2020
02:31pm, Monday, 16'th Mar 2020
Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.
First U.S. patients treated with Palforzia for peanut allergy
12:40pm, Monday, 16'th Mar 2020
Aimmune Therapeutics (NASDAQ:AIMT) announces that the first patients in the U.S. are being treated with PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first approved treatment for pe
Aimmune Therapeutics Inc:
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
12:00pm, Monday, 16'th Mar 2020
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
Aimmune Therapeutics Inc (NASDAQ:AIMT) Given Consensus Recommendation of "Buy" by Brokerages
06:20am, Monday, 16'th Mar 2020
Aimmune Therapeutics Inc (NASDAQ:AIMT) has earned a consensus recommendation of “Buy” from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. One research analy
Aimmune's Palforzia shows durable effect in follow-on peanut allergy study
02:38pm, Saturday, 14'th Mar 2020
New data from an open-label follow-on study, ARC004, from the 52-week PALISADE trial showed a durable treatment effect of Aimmune Therapeutics' (NASDAQ:AIMT) Palforzia [Peanut (Arachis hypogaea) Aller
BRIEF-Aimmune Announces New Palforzia Data After 18 And 24 Months Of Treatment
09:06pm, Friday, 13'th Mar 2020
Aimmune Therapeutics Inc:
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability
